Medtronic plc
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net sales | $33.54B+3.6% | $32.36B+3.6% | $31.23B-1.4% | $31.69B+5.2% | $30.12B |
| Cost of products sold, excluding amortization of intangible assets | $11.63B+3.7% | $11.22B+4.6% | $10.72B+5.7% | $10.14B-3.2% | $10.48B |
| Research and development expense | $2.73B-0.1% | $2.73B+1.4% | $2.70B-1.8% | $2.75B+10.1% | $2.49B |
| Selling, general, and administrative expense | $10.85B+1.1% | $10.74B+3.1% | $10.41B+1.2% | $10.29B+1.4% | $10.15B |
| Amortization of intangible assets | $1.81B+6.7% | $1.69B-0.3% | $1.70B-2.0% | $1.73B-2.8% | $1.78B |
| Restructuring charges, net | $267.0M+18.1% | $226.0M-39.7% | $375.0M+525.0% | $60.0M-79.5% | $293.0M |
| Certain litigation charges, net | $317.0M+112.8% | $149.0M+596.7% | -$30.0M-131.6% | $95.0M-19.5% | $118.0M |
| Other operating (income) expense, net | -$23.0M-105.0% | $464.0M+454.2% | -$131.0M-115.2% | $862.0M+173.7% | $315.0M |
| Operating profit | $5.96B+15.8% | $5.14B-6.2% | $5.49B-4.6% | $5.75B+28.3% | $4.48B |
| Other non-operating income, net | -$402.0M+2.4% | -$412.0M+20.0% | -$515.0M-61.9% | -$318.0M+5.4% | -$336.0M |
| Interest expense, net | $729.0M+1.4% | $719.0M+13.1% | $636.0M+15.0% | $553.0M-40.2% | $925.0M |
| Income before income taxes | $5.63B+16.4% | $4.84B-9.8% | $5.36B-2.8% | $5.52B+41.6% | $3.90B |
| Income tax provision | $936.0M-17.4% | $1.13B-28.3% | $1.58B+246.5% | $456.0M+72.1% | $265.0M |
| Net income | $4.69B+26.6% | $3.71B-2.1% | $3.78B-25.2% | $5.06B+39.4% | $3.63B |
| Net income attributable to noncontrolling interests | -$29.0M-3.6% | -$28.0M-7.7% | -$26.0M-18.2% | -$22.0M+8.3% | -$24.0M |
| Net income attributable to Medtronic | $4.66B+26.8% | $3.68B-2.2% | $3.76B-25.4% | $5.04B+39.7% | $3.61B |
| Basic earnings per share (in dollars per share) | $3630000.00+31.0% | $2770000.00-2.1% | $2830000.00-24.5% | $3750000.00+39.9% | $2680000.00 |
| Diluted earnings per share (in dollars per share) | $3610000.00+30.8% | $2760000.00-2.1% | $2820000.00-24.4% | $3730000.00+40.2% | $2660000.00 |
| Basic weighted average shares outstanding (in shares) | 1.29B-3.2% | 1.33B-0.2% | 1.33B-0.9% | 1.34B-0.2% | 1.34B |
| Diluted weighted average shares outstanding (in shares) | 1.29B-3.0% | 1.33B-0.2% | 1.33B-1.4% | 1.35B-0.2% | 1.35B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Medtronic delivered Q4 revenue of $9.8B with non-GAAP EPS of $1.55, beating guidance, and achieved highest annual revenue growth in 10 years at $36.4B
“Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | Sale | 52.5K | $97.71 | $5.13M | 32.8K | View |
Informational purposes only, not investment advice.